The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Daiichi Sankyo
Travel, Accommodations, Expenses - Bayer; Roche

Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).
 
Cora N. Sternberg
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genzyme; Incyte; Medscape; Merck; MSD; Pfizer; Roche; Roche/Genentech; UroToday
 
Karim Fizazi
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer; Curevac (Inst); ESSA (Inst); Janssen Oncology; Orion Pharma GmbH; Sanofi
Travel, Accommodations, Expenses - Amgen; Janssen
 
Fred Saad
Honoraria - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Pfizer (Inst); Sanofi (Inst)
 
Neal D. Shore
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Merck; Myovant Sciences; Pfizer; Tolmar
Speakers' Bureau - Bayer; Dendreon; Janssen
 
Ugo De Giorgi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; MSD; Pfizer; Sanofi
Research Funding - AstraZeneca (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen; Pfizer; Roche
 
David F. Penson
Consulting or Advisory Role - Astellas Pharma; Dendreon
 
Ubirajara Ferreira
No Relationships to Disclose
 
Petro Ivashchenko
No Relationships to Disclose
 
Eleni Efstathiou
Honoraria - Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Merck; Sanofi
Research Funding - Astellas Pharma; Janssen; Pfizer; Sanofi
 
Katarzyna Madziarska
No Relationships to Disclose
 
Michael Paul Kolinsky
Honoraria - Bayer; Janssen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; Merck
 
Daniel Iracema Cubero
No Relationships to Disclose
 
Bettina Noerby
Stock and Other Ownership Interests - Lundbeck (I); Novo Nordisk (I); Teva (I)
 
Fabian Zohren
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Xun Lin
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Katharina Modelska
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jennifer Sugg
Employment - Astellas Pharma
Stock and Other Ownership Interests - AstraZeneca
 
Joyce Leta Steinberg
Employment - Astellas Pharma
Stock and Other Ownership Interests - Amgen (I)
Travel, Accommodations, Expenses - Astellas Pharma
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; Astellas Pharma; Genentech; MLI PeerView; PER; PER; Phillips Gilmore Oncology; projects in Knowledge; Research to Practice; Research to Practice; Sanofi
Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Genentech; Genentech/Roche; Pfizer